|
|
|
Board of Directors |
|
Glenn Kawasaki, Ph.D.
|
Dr. Kawasaki has 24 years of experience in start-up biotechnology companies. He was the first scientist (1981) and chair of the Science Board at ZymoGenetics, Inc., today a one-billion-dollar public corporation. He has a Ph.D. in Genetics (1979), an M.B.A. (1986), and a J.D. (1995) each from the University of Washington. Dr. Kawasaki was a research fellow at Harvard Medical School from 1979-81 and was an undergraduate at U.C. Berkeley, where he earned a B.S. in Genetics and an A.B. in Zoology. In 1989 he founded Aptein, Inc., which was based on Dr. Kawasaki's invention now known as "ribosome display" for engineering antibodies and other proteins. He was the President, CEO, and Research Director of this Seattle company. Aptein was sold to Cambridge Antibody Technology, a U.K. firm, in 1998. In 1999, Dr. Kawasaki founded Catch Incorporated, which developed and now sells a novel test for homocysteine, a compound linked to cardiovascular diseases, Alzheimer's Disease, glaucoma, and other ailments. Dr. Kawasaki remains an executive officer and director of Catch but is not an employee of the Bothell, WA, firm. He is a founder and director of Sound Pharmaceuticals, another Seattle start-up (2001), which is focused on preventing and restoring hearing loss. Dr. Kawasaki has 14 U.S. patents and over a hundred foreign related patents. Dr. Kawasaki is also a Vice President of the Pacific Northwest Ballet Company in Seattle. |
|
Ali Arjomand, Ph.D.
|
Dr. Arjomand is founder of Accium BioSciences and is responsible for Accium’s commercial AMS services and operations. He serves as Scientific Director for Accium's AMS-based studies and is responsible for each sponsor's bioanalytical project. Dr. Arjomand obtained his Doctorate in 1998 from the University of California in Davis under the guidance of Dr. Andrew Clifford. He designed and conducted the first human microdosing study using AMS in a joint research effort with Lawrence Livermore National Laboratory (see publications). Prior to co-founding Accium, Dr. Arjomand was Director of Technical Business Development at CombiMatrix Corporation, a publicly traded genomics biotechnology company. As the sixteenth employee hired, Dr. Arjomand co-led the development of commercialization strategies and oversaw the expansion of the company’s DNA chip products into the U.S. and Asian markets. Prior to joining CombiMatrix, Dr. Arjomand was lead technical consultant for chromatography at Bio-Rad Laboratories, a $1B supplier of life science and diagnostics products. |
|
Jon Ruckle, M.D.
|
Dr. Ruckle is a Clinical Investigator with 14 years full time research experience, primarily in Phase I clinical trials. He was the founding Medical Director at Northwest Kinetics in Tacoma, Washington in 1995 which was later acquired by Charles River Laboratories. He then led the development of Phase I studies at Radiant Research in Honolulu, Hawaii from August 2000 until it was acquired by Covance in May 2006. He remained as Medical Director at Covance Honolulu through July 2008. Dr. Ruckle has been the Principal Investigator for approximately 300 clinical trials, mostly in Phase I. Study areas include Japanese "bridging" studies, First-Time-In-Humans, Biologics, microdose and ADME studies, and various clinical domains and special populations including Diabetes, Osteoporosis, healthy elderly, pediatrics, osteoarthritis, hypercholesterolemia, and hypertension. |
| Copyright © Accium BioSciences, Inc. 2004-2010 | |
